Latest: FDA Approves New Biosimilar for Oncology Treatment

STAT+: Illumina CEO sees path to stable growth, even as its academic customers face funding uncertainty

0 Mins
CEO Jacob Thaysen sees Illumina on track to meet his original goal of high single-digit revenue growth by 2027 despite unexpected headwinds.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago